Etzer Darout
Stock Analyst at Barclays
(4.32)
# 408
Out of 5,093 analysts
149
Total ratings
50.83%
Success rate
17.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $119 | $88.19 | +34.94% | 4 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Overweight | $28 → $36 | $41.86 | -14.00% | 10 | Nov 25, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $22 → $35 | $19.99 | +75.09% | 1 | Nov 24, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $11 → $28 | $11.08 | +152.71% | 1 | Nov 24, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $4 → $9 | $2.29 | +293.01% | 1 | Nov 24, 2025 | |
| INCY Incyte | Maintains: Overweight | $101 → $115 | $96.72 | +18.90% | 1 | Nov 24, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $44 → $45 | $45.56 | -1.23% | 7 | Nov 17, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Underweight | $25 → $21 | $28.98 | -27.54% | 2 | Nov 11, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $83 → $70 | $44.13 | +58.62% | 2 | Nov 11, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $58 → $56 | $35.29 | +58.71% | 3 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $88 | $91.23 | -3.54% | 4 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $48 | $16.17 | +196.85% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $16 | $13.26 | +20.66% | 6 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $41 | $41.79 | -1.89% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $6 → $23 | $17.38 | +32.34% | 7 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $17.73 | -9.76% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $6 | $3.95 | +52.09% | 12 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $4.19 | +1,355.85% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $31.31 | +53.31% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $74.65 | +67.45% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $16 | $8.86 | +80.69% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $121.27 | +17.09% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $112 → $97 | $96.36 | +0.66% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $2.56 | +290.63% | 5 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.39 | +115.83% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $4.26 | +205.16% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $96.25 | +48.57% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $3.29 | -8.68% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $21.04 | +66.35% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.74 | +3,531.12% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $2.52 | +971.43% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $106.89 | +25.36% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $31.29 | +53.40% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $132.35 | -9.33% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.08 | +458.14% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $90.35 | -9.24% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.43 | +328.89% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $421.34 | -59.65% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $54.70 | -1.28% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $66.24 | -42.63% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $3.31 | +1,471.00% | 1 | Mar 28, 2018 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $70 → $119
Current: $88.19
Upside: +34.94%
Terns Pharmaceuticals
Nov 25, 2025
Maintains: Overweight
Price Target: $28 → $36
Current: $41.86
Upside: -14.00%
Syndax Pharmaceuticals
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $19.99
Upside: +75.09%
Kura Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $11.08
Upside: +152.71%
Iovance Biotherapeutics
Nov 24, 2025
Maintains: Overweight
Price Target: $4 → $9
Current: $2.29
Upside: +293.01%
Incyte
Nov 24, 2025
Maintains: Overweight
Price Target: $101 → $115
Current: $96.72
Upside: +18.90%
Scholar Rock Holding
Nov 17, 2025
Maintains: Overweight
Price Target: $44 → $45
Current: $45.56
Upside: -1.23%
Celldex Therapeutics
Nov 11, 2025
Maintains: Underweight
Price Target: $25 → $21
Current: $28.98
Upside: -27.54%
AnaptysBio
Nov 11, 2025
Maintains: Overweight
Price Target: $83 → $70
Current: $44.13
Upside: +58.62%
RAPT Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $58 → $56
Current: $35.29
Upside: +58.71%
Nov 7, 2025
Maintains: Overweight
Price Target: $72 → $88
Current: $91.23
Upside: -3.54%
Nov 7, 2025
Maintains: Overweight
Price Target: $47 → $48
Current: $16.17
Upside: +196.85%
Nov 6, 2025
Maintains: Overweight
Price Target: $15 → $16
Current: $13.26
Upside: +20.66%
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $40 → $41
Current: $41.79
Upside: -1.89%
Oct 29, 2025
Upgrades: Overweight
Price Target: $6 → $23
Current: $17.38
Upside: +32.34%
Oct 21, 2025
Maintains: Underweight
Price Target: $13 → $16
Current: $17.73
Upside: -9.76%
Oct 21, 2025
Maintains: Overweight
Price Target: $3.5 → $6
Current: $3.95
Upside: +52.09%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $4.19
Upside: +1,355.85%
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $31.31
Upside: +53.31%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $74.65
Upside: +67.45%
Oct 13, 2025
Initiates: Overweight
Price Target: $16
Current: $8.86
Upside: +80.69%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $121.27
Upside: +17.09%
Sep 30, 2025
Downgrades: Equal-Weight
Price Target: $112 → $97
Current: $96.36
Upside: +0.66%
Sep 23, 2025
Maintains: Overweight
Price Target: $8 → $10
Current: $2.56
Upside: +290.63%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.39
Upside: +115.83%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $4.26
Upside: +205.16%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $96.25
Upside: +48.57%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $3.29
Upside: -8.68%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $21.04
Upside: +66.35%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.74
Upside: +3,531.12%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $2.52
Upside: +971.43%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $106.89
Upside: +25.36%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $31.29
Upside: +53.40%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $132.35
Upside: -9.33%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.08
Upside: +458.14%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $90.35
Upside: -9.24%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.43
Upside: +328.89%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $421.34
Upside: -59.65%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $54.70
Upside: -1.28%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $66.24
Upside: -42.63%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $3.31
Upside: +1,471.00%